Text size :

Tumors, Aiom: “The Periodic Table of Mutations arrives in Italy, AI at the service of precision medicine” (2)

ADNKRONOS

November 14, 2026

(Adnkronos Health) – “The molecular characterization of tumors is decisive for therapeutic choices in a high percentage of oncology patients – states Massimo Di Maio, Aiom president -. In recent years, we have also learned that tumor biology changes during the course of the disease. This increases therapeutic options whose appropriateness depends on the presence or absence of specific alterations. The ‘Periodic Table of Mutations’ platform represents an innovative project, the first ever realized in our country, and we are very grateful to our Siapec colleagues for this initiative. The platform is an expression of the importance of collaboration between our Scientific Societies, and represents the advanced frontier of precision medicine. It is no longer just about evaluating a specific gene for the choice of an effective therapy. We have now moved on to an extremely in-depth analysis of every single mutation that can have a specific marker. Furthermore, the volume of studies and scientific evidence produced in recent years is truly impressive and constantly evolving.”

“The project we are presenting today, on the occasion of our National Congress, represents further evidence of the consolidated and fruitful collaboration between Aiom and Siapec-Iap – emphasizes Rossana Berardi, Aiom president-elect -. Modern oncology is increasingly precision oncology, in which in-depth knowledge of the biological and genomic characteristics of the tumor is fundamental to guide therapeutic choices and offer each patient the most appropriate treatment. This approach is concretely transforming treatment prospects, even in the most advanced stages of the disease, contributing to the significant progress we are observing in terms of treatment efficacy and survival. In this scenario, the synergy between medical oncologists and anatomical pathologists plays a strategic and essential role, so that precision medicine can translate into concrete, timely, and accessible therapeutic opportunities for all patients.”

The platform “being presented today is a project in continuous evolution: after starting with EGFR mutations in advanced lung cancer, one of the first and most consolidated examples of clinical application of precision oncology, it is progressively expanding its content to include all validated biomarkers used in clinical practice – adds Berardi -. The objective is to provide professionals with a shared, updated, and easy-to-consult tool that can become a reference point in daily clinical practice for members of both Scientific Societies. Because today the real challenge is not only to have increasingly innovative scientific knowledge and therapies, but to ensure that these opportunities translate into appropriate diagnostic-therapeutic pathways and equitable access to the best care throughout the national territory.”

Jiji Press

Related

Page TOP